Lynparza (olaparib tablets – AstraZeneca) — Cigna
Breast Cancer – Recurrent or Metastatic Disease
Initial criteria
- Patient is age ≥ 18 years
- Patient has recurrent or metastatic disease
- Patient has BRCA mutation-positive breast cancer OR germline PALB2 mutation-positive breast cancer
Approval duration
1 year